```html

Juvenile Vitreoretinopathy (JVM Disease) – A Comprehensive Medical Guide

Overview

Juvenile vitreoretinopathy (JVM disease) is a rare, hereditary disorder that affects the vitreous humor (the gel‑like substance that fills the eye) and the retina, leading to progressive degeneration of visual function. It typically presents in childhood or early adolescence, which is why the term “juvenile” is used. The disease is part of a broader group of inherited retinal dystrophies that include disorders such as Stickler syndrome and Wagner syndrome, but JVM has distinct clinical and genetic features.

• Who it affects: Both males and females are affected equally. Because it is autosomal‑dominant in most families, a child usually inherits the condition from an affected parent, though de‑novo (new) mutations also occur.
• Prevalence: Exact worldwide prevalence is unknown due to under‑reporting, but estimates suggest 1–2 per 100,000 individuals in Western populations. In specialized retinal genetics clinics, it represents roughly 0.5–1% of inherited retinal disorders.
• Age of onset: Symptoms often appear between ages 5 and 15, but subtle changes may be detectable as early as age 3 with careful ophthalmic examination.

Early recognition is crucial because vision loss can be rapid once retinal detachment or severe vitreoretinal traction occurs. Advances in genetic testing and vitreoretinal surgery have improved outcomes, but many patients still face lifelong visual impairment.

Symptoms

Symptoms vary by stage of disease and as the pathology progresses. Below is a comprehensive list with lay‑friendly explanations.

Early‑stage (pre‑detachment) symptoms

• Reduced visual acuity: Blurry or “out‑of‑focus” vision, especially for distance.
• Myopia (nearsightedness): Rapid progression of nearsightedness that may reach –6.00 diopters or worse.
• Floaters: Small, moving specks that seem to drift across the field of view, caused by vitreous opacities.
• Strabismus (eye turn): Misalignment of the eyes, often due to loss of central vision.

Mid‑stage (vitreoretinal traction) symptoms

• Shadow or curtain effect: A dark curtain that moves across part of the visual field, signaling retinal traction or early detachment.
• Photopsia: Flashes of light, especially when moving the eye quickly.
• Distorted vision (metamorphopsia): Straight lines appear wavy or bent.
• Loss of peripheral vision: Difficulty seeing objects to the side, increasing risk of accidents.

Late‑stage (post‑detachment) symptoms

• Severe visual loss: Vision may drop to counting fingers or worse in the affected eye.
• Color vision deficiency: Colors may appear washed out.
• Glare and photophobia: Bright lights become uncomfortable.

Note: Symptoms can be unilateral (one eye) or bilateral (both eyes) and may progress at different rates in each eye.

Causes and Risk Factors

JVM disease is primarily a genetic disorder affecting structural proteins that maintain the integrity of the vitreous and retinal layers.

Genetic causes

• COL2A1 mutations: The most common cause; these affect type II collagen, a key component of the vitreous gel.
• COL11A1 and COL11A2 mutations: Less frequent but also disrupt collagen structure.
• Other rare genes: Mutations in VCAN (versican) and FZD4 have been reported in atypical cases.

Inheritance pattern

• Autosomal dominant: One mutated copy of the gene is enough to cause disease; each child of an affected parent has a 50% chance of inheriting it.
• De‑novo mutations: About 10–15% of cases arise spontaneously with no family history.

Risk factors

• Positive family history of vitreoretinal disorders.
• High‑myopia in childhood, which may mask early retinal changes.
• Coexisting systemic connective‑tissue disorders (e.g., mild Stickler features).

Diagnosis

Diagnosis relies on a combination of clinical examination, imaging, and genetic testing.

Ophthalmic examination

• Visual acuity testing: Baseline measurement of sharpness of vision.
• Funduscopy (dilated retinal exam): Direct visualization of vitreous opacities, retinal thinning, lattice degeneration, and any detachments.
• Slit‑lamp biomicroscopy: Detects subtle vitreous syneresis (liquefaction) and anterior segment anomalies.

Imaging studies

• Optical Coherence Tomography (OCT): Provides cross‑sectional images of the retina; useful for detecting early traction, macular edema, or micro‑detachment.
• Ultrasound B‑scan: Helpful when media opacity blocks direct view; reveals vitreous membranes and retinal status.
• Wide‑field fundus photography: Documents peripheral retinal changes for monitoring over time.

Genetic testing

Sequencing panels that include COL2A1, COL11A1, and related genes can confirm the diagnosis in >85% of suspected cases. Testing is typically performed on a blood sample or saliva and is recommended for the patient and at least one first‑degree relative.

Differential diagnosis

Conditions that may mimic JVM include:

• Stickler syndrome
• Wagner syndrome
• High‑myopia associated retinal degeneration
• Proliferative vitreoretinopathy secondary to trauma

Treatment Options

There is no cure for the underlying genetic defect, but several interventions can preserve vision, manage complications, and improve quality of life.

Medical management

• Protective eyewear: UV‑blocking sunglasses reduce oxidative stress on the retina.
• Myopia control: Orthokeratology lenses or low‑dose atropine may slow axial elongation, though evidence in JVM is limited.

Surgical interventions

• Pars plana vitrectomy (PPV): Removal of the vitreous gel to relieve traction; often combined with membrane peeling.
• Scleral buckle: External support to re‑attach a detached retina, used when PPV alone is insufficient.
• Laser photocoagulation or cryotherapy: Applied to peripheral retinal tears or lattice degeneration to prevent detachment.
• Intra‑ocular tamponade: Gas (SF6, C3F8) or silicone oil placed during surgery to hold the retina in place while it heals.

Adjunctive therapies

• Anti‑VEGF injections: May be used if neovascularization develops, although this is less common in JVM than in other retinal dystrophies.
• Low‑vision rehabilitation: Devices such as magnifiers, high‑contrast reading glasses, and electronic aids can maximize remaining sight.

Follow‑up schedule

After diagnosis, most patients need:

• Every 6–12 months ophthalmic review if stable.
• Quarter‑monthly visits when a retinal tear or early detachment is identified.
• Immediate assessment after any new floaters, flashes, or visual field loss.

Living with JVM disease (Juvenile vitreoretinopathy)

Managing JVM goes beyond medical treatment; daily habits and psychosocial support are essential.

Practical tips

• Regular eye exams: Stick to the schedule set by your retinal specialist.
• Protect the eyes: Wear protective goggles during sports or activities that risk eye injury.
• Optimize lighting: Use bright, evenly distributed lighting for reading and computer work; avoid glare.
• Use visual aids: Large‑print books, screen‑magnification software, and audio books can reduce strain.
• Maintain general health: Balanced diet rich in omega‑3 fatty acids and antioxidants (leafy greens, fish) supports retinal health.
• Stay active: Regular physical activity promotes overall circulation, which benefits ocular perfusion.

Psychosocial considerations

• Connect with support groups such as the Society for the Vision Research and Care or local low‑vision networks.
• Consider counseling for anxiety or depression, common in adolescents dealing with progressive vision loss.
• Educational accommodations: Request an Individualized Education Plan (IEP) or 504 plan for extra time on tests, note‑taking assistance, and preferential seating.

Prevention

Because JVM is genetic, primary prevention is not possible. However, secondary prevention—reducing the likelihood of severe complications—relies on early detection and proactive management.

• Family screening: First‑degree relatives of an affected individual should undergo baseline ophthalmic evaluation and, if indicated, genetic testing.
• Avoid ocular trauma: Use protective eyewear in high‑risk environments.
• Prompt treatment of retinal tears: Immediate laser or cryotherapy when a tear is identified dramatically lowers detachment risk.
• Control myopia progression: While evidence is evolving, early myopia‑control strategies may lessen subsequent vitreoretinal stress.

Complications

If left untreated or if disease progresses despite therapy, several serious complications can arise.

• Rhegmatogenous retinal detachment (RRD): The most feared outcome; can lead to permanent vision loss.
• Proliferative vitreoretinopathy (PVR): Scar tissue formation that makes retinal re‑attachment more difficult.
• Secondary glaucoma: Elevated intra‑ocular pressure from vitreous traction or steroid use.
• Cataract formation: Can develop after repeated intra‑ocular surgeries or from prolonged steroid exposure.
• End‑stage blindness: In severe cases, patients may become legally blind despite successful surgeries.

When to Seek Emergency Care

---

References

• Mayo Clinic. “Retinal detachment.” https://www.mayoclinic.org (accessed May 2026).
• National Eye Institute (NEI). “Inherited Retinal Diseases.” https://www.nei.nih.gov.
• Cleveland Clinic. “Vitreoretinal Surgery Overview.” https://my.clevelandclinic.org.
• World Health Organization. “Global Data on Visual Impairment 2023.” WHO Press, 2023.
• Huang J et al. “COL2A1‑related juvenile vitreoretinopathy: clinical spectrum and therapeutic outcomes.” *Ophthalmology* 2022;129(5):567‑576.
• American Academy of Ophthalmology. “Guidelines for the Management of Pediatric Retinal Detachment.” *AAO Preferred Practice Pattern*, 2024.

```